TABLE 1.
Baseline characteristics of patients.
| Characteristics | Number of patients (%) |
|---|---|
| Gender | |
| Male | 19 (61.3) |
| Female | 12 (38.7) |
| Age | |
| ≥42 years | 17 (54.8) |
| <42 years | 14 (45.2) |
| KPS score | |
| ≥60 | 20 (64.5) |
| <60 | 11 (35.5) |
| Grade of histology | |
| 4 | 21 (67.7) |
| 3 | 10 (32.3) |
| Tumor location | |
| Multifocal/dissemination | 22 (71.0) |
| Focal | 9 (29.0) |
| MGMT promoter status | |
| Methylation | 12 (38.7) |
| Unmethylation | 19 (61.3) |
| IDH status | |
| Wild type | 22 (71.0) |
| Mutation | 9 (29.0) |
| 1p/19q deletion | |
| Positive | 7 (22.6) |
| Negative | 16 (51.6) |
| Unknown | 8 (25.8) |
| Line of previous treatment for recurrent disease | |
| 0 | 7 (22.6) |
| 1 | 13 (41.9) |
| ≥2 | 11 (35.5) |
| Previous anti-angiogenic agents | |
| Yes | 13 (41.9) |
| No | 18 (58.1) |
| Previous re-operation | |
| Yes | 11 (35.5) |
| No | 20 (64.5) |
| Previous re-radiation | |
| Yes | 6 (19.4) |
| No | 25 (80.6) |
| Study treatment | |
| Anlotinib plus temozolomide | 14 (45.2) |
| Anlotinib | 17 (54.8) |
KPS, Karnofsky Performance Status score; MGMT, O6-methylguanine-DNA methyltransferase; IDH, isocitrate dehydrogenase.